OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 TherapeuticsGlobeNewsWire • 07/12/21
BioReference Laboratories Announces First COVID-19 Testing Program for Cruise IndustryPRNewsWire • 06/22/21
OPKO Health, Nicoya Therapeutics Ink Rayaldee Pact For Hyperparathyroidism In Greater ChinaBenzinga • 06/21/21
OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya TherapeuticsGlobeNewsWire • 06/21/21
OPKO Health Offloads Fill and Finish Manufacturing Facility in Ireland To Horizon TherapeuticsBenzinga • 06/17/21
OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in IrelandGlobeNewsWire • 06/17/21
OPKO Health, Inc. (OPK) CEO Phillip Frost presents at Jefferies 2021 Virtual Healthcare Conference (Transcript)Seeking Alpha • 06/02/21
OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to ViforGlobeNewsWire • 05/24/21
Is the Options Market Predicting a Spike in OPKO Health (OPK) Stock?Zacks Investment Research • 05/20/21
OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior NoteholdersGlobeNewsWire • 05/07/21
OPKO Health, Inc. (OPK) CEO Phillip Frost on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/29/21
OPKO Health Reports 2021 First Quarter Business Highlights and Financial ResultsGlobeNewsWire • 04/28/21